Our technology
Therapeutic proteins
Therapeutic proteins are cutting-edge treatments for complex diseases including cancer, autoimmune diseases, infectious diseases and beyond.
These proteins are produced in living cell factories in the laboratory.
The most commonly used therapeutic proteins are antibodies, favoured due to their high specificity for their target in the body.
What is N-glycosylation?
Two-thirds of the therapeutic proteins used in the clinic today have sugar molecules, also known as N-glycans, attached to their surface.
N-glycosylation is a post-translational modification that is added to a protein during its production in a cell.
kyron.bio is pioneering tomorrow's therapeutics using glycan engineering.
We use an innovative cell line engineering approach combined with structure guided design of therapeutics to precision control glycosylation.
Our approach
This novel approach opens up a new era of antibody engineering, bringing treatments to patients who are most in need.
Antibodies have had significant success, yet major challenges remain in controlling the patient immune response to the therapeutic, ensuring proper circulation time, and achieving optimal therapeutic function.
At kyron.bio, we are leveraging N-glycosylation to solve these issues.
Despite their importance, N-glycans are highly heterogenous, and harnessing their therapeutic potential has to date been underexploited.
Why is N-glycosylation important?
N-glycans are vitally important for protein function, as they influence the protein's structure, where it is targeted to, how it interacts with the immune system, and how long it remains in circulation in the human body.